Cancer vaccines at an inflexion point: what next? by Bot, Adrian et al.
EDITORIAL Open Access
Cancer vaccines at an inflexion point: what next?
Adrian Bot
1, Mihail Obrocea
2 and Francesco M Marincola
3*
Abstract
With the approval of the first therapeutic cancer vaccines for veterinarian and human use, the field reached a
significant milestone after a considerable interval of tumultuous research and development marked by numerous
ups and downs. As the mechanism of action and clinical benefit afforded by this class of agents are starkly
different from that of conventional or small targeted therapies for cancer, there are still numerous hurdles that
need to be overcome to fully unleash their potential. These challenges and efforts are illustrated in a book just
published on this subject, a non-exhaustive yet representative synopsis of the latest advances in cancer vaccine
technologies in various stages of development. Major lessons resulting from clinical testing of cancer vaccines and
other immune interventions, are being integrated in novel, cutting edge platform technologies that blur the
distinction between passive and active immunotherapies as well as carry the promise of fundamentally changing
and improving the management of patients with cancer.
It took more than a century after the first published
description of cancer treatment through active immu-
notherapy by Coley [1], half a century since the formula-
tion of the “cancer immunosurveillance” hypothesis by
Burnet [2], and several decades since the discovery of
dendritic cells by Steinman [3], MHC class I-restricted
cytotoxic lymphocytes by Zinkernagel and Doherty [4]
or tumor associated-antigens by Boon and Rosenberg
[5,6], to finally witness the arrival of the first commer-
cial veterinarian [7] and human [8] antigen-targeted
therapeutic cancer vaccines.
The mere subject of cancer vaccines could still trigger
hot debates, finding its fervent opponents or its staunch
supporters in the scientific and clinical community. As
the arguments of the former are firmly anchored in the
belief that the immune system has essentially evolved to
ensure anti-microbial as opposed to anti-tumor moni-
toring, the latter segment of the scientific community
sees the appealing and imminent possibility of translat-
ing the immunity’s major features to groundbreaking
therapies.
The skepticism around immune interventions and in
particular cancer vaccines had objective roots as key
questions and hurdles needed to be tackled to fully
unleash their potential in clinic: a) their indirect
mechanism of action manifests through a rather subtle
and sometimes delayed clinical benefit; b) the latter
could be evident in most cases at cohort rather than
patient’s individual level; c) there are very few instances
of objective, durable responses owing to poorly under-
stood mechanistic circumstances; and d) the reliability
of current immune correlates of clinical benefit was
questionable despite significant progress in immunology.
All these issues translated into an exceedingly difficult,
risky and expensive process of developing such thera-
peutic agents. The decision-making for optimization,
advancement to next stage or termination has been
essentially deferred to large phase 2 or 3 clinical trials,
unless the industrial sponsor succumbed to inherent
challenges of a competitive market economy. The pro-
ponents of therapeutic cancer vaccines, in turn, advo-
cated the need to rationally and systematically tackle the
general challenges from above. However, vaccine tech-
nologies also present specific challenges: autologous cell
based vaccines have expensive and cumbersome manu-
facturing processes with economical and commercial
implications, while “off the shelf” v a c c i n ep l a t f o r mt e c h -
nologies have yet to show clinical benefit.
Marking the arrival of the first antigen-targeted cancer
vaccines on the market, the book published this month
[9] aims to also provide the readership with a perspec-
tive across key platform technologies in development,
challenges and hurdles ahead as well as strategies to
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microbial vaccines, a new generation of potent synthetic
vaccine candidates facilitated by the discovery of Toll-
like receptors [10] emerged, with more favorable eco-
nomics associated with their development and optimiza-
tion, carrying the promise of reducing the optimization
cycle and propelling this field towards other regulatory
approvals. Along with efforts to improve on vaccines’
intrinsic potency, much of the current focus is dedicated
to advancing reliable predictive biomarkers and immune
monitoring resulting from a rationale systems-biology
approach. These three key areas of research aim to max-
imize the potential of cancer vaccines through their
unique mechanism of action, in the quest to generate
durable responses and tackle disseminated disease.
Nevertheless, in this darwinistic environment repre-
senting today’s “state of affairs” in cancer therapeutics
development, platform technologies cross-communicate
with potentially astonishing outcomes. This is reflected
by new trends and emerging technologies [9], essentially
obscuring the distinction between passive and active
immunotherapies. From efforts directed at whole
immune system reengineering through T cell program-
ming and adoptive cell transfer therapies, we should
also expect key learning with a potential to translate to
very innovative and “off-the-shelf”, widely applicable
immune interventions. As this phenomenon of cross-
fertilization between different platform technologies
evolves in front of our eyes, a natural question comes to
our mind: could the concept of “therapeutic cancer vac-
cination” survive as such or rather evolve past its origi-
nal definition, in this rapidly changing landscape?
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